Clarity Pharmaceuticals Ltd. has additionally completed several clinical trials in patients with biochemical recurrence of prostate cancer following definitive therapy using 64Cu-SAR-bisPSMA (COBRA- NCT05249127) and a Phase I/IIa trial, Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate (SECuRE-/NCT04868604). The gene discussed is FOLH1; the disease is prostate carcinoma.